Tepezza™ (teprotumumab-trbw)

Tepezza is covered only for the FDA‑approved indication of thyroid eye disease (not for mild disease or non‑FDA uses) regardless of activity/duration, and is not covered for patients who have already completed an 8‑dose course. Approval (limited to 6 months) requires age ≥18, documentation of at least moderate severity (e.g., lid retraction ≥2 mm, moderate/severe soft‑tissue involvement, proptosis ≥3 mm for race/sex, or diplopia Gorman score 2–3), prescribing by or in consultation with an ophthalmologist, endocrinologist, or thyroid‑eye specialist, and documentation of prior Tepezza doses.

"Tepezza is indicated for the treatment of thyroid eye disease, regardless of thyroid eye disease activity or duration."

Sign up to see full coverage criteria, indications, and limitations.